• This email address is being protected from spambots. You need JavaScript enabled to view it.

Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.

Francis, J., Zvada, S.P., Denti, P., Hatherill, M., Charalambous, S., Mungofa, S., Dawson, R., Dorman, S., Gupte, N., Wiesner, L. and Jindani, A., 2019. Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis. Antimicrobial Agents and Chemotherapy, pp.AAC-01964. [Epub ahead of print]


© 2025 The Aurum Institute. All Rights Reserved.